Published in Health Qual Life Outcomes on May 12, 2006
Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis (2015) 0.94
Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther (2010) 0.86
Hepatitis C virus infection. N Engl J Med (2001) 18.67
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet (1998) 14.31
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep (1998) 12.78
Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med (2000) 5.58
Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med (1995) 5.55
Epidemiology of hepatitis C. Hepatology (1997) 4.90
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med (1989) 4.69
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med (1997) 3.49
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology (1999) 2.67
Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol (2003) 2.42
Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology (2002) 2.27
Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology (1997) 1.51
The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol (2001) 1.50
Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 1.49
The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol (2004) 1.22
The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol (1995) 1.19
Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci (1997) 1.15
Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol (1999) 1.07
Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat (2004) 0.96
Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment. Dig Dis Sci (2006) 0.95
The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol (2005) 2.42
Overexpression of cyclooxygenase 2 in hamartomatous polyps of Peutz-Jeghers syndrome. Am J Gastroenterol (2003) 0.88
Correlation of staining for LKB1 and COX-2 in hamartomatous polyps and carcinomas from patients with Peutz-Jeghers syndrome. J Histochem Cytochem (2003) 0.83
Psychosocial impact of Peutz-Jeghers Syndrome. Fam Cancer (2008) 0.81
Barrett's Esophagus: Emerging Knowledge and Management Strategies. Patholog Res Int (2012) 0.78
The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program. Hered Cancer Clin Pract (2010) 0.78
Colorectal cancer screening in high-risk groups is increasing, although current smokers fall behind. Cancer (2014) 0.76
Screening for Familial Colorectal Cancer Risk amongst Colonoscopy Patients New to an Open-Access Endoscopy Center. ISRN Gastroenterol (2012) 0.75
Synchronous proximal polyps and cancer in patients with polyps detected at sigmoidoscopy: results of a single, rural-based sigmoidoscopy clinic. Dig Dis Sci (2002) 0.75